Results 101 to 110 of about 9,202 (225)

Lysosome‐Acidifying Nanoparticles Rescue A30P α‐Synuclein Induced Neuronal Death in Cellular and Drosophila Models of Parkinson's Disease

Advanced Healthcare Materials, Volume 15, Issue 22, 12 June 2026.
Lysosome‐targeted acidic nanoparticles based on a biodegradable poly(ethylene tetrafluorosuccinate‐co‐succinate) copolymer are engineered to restore impaired lysosomal acidification through pH‐responsive intracellular degradation. Localized acid release enhances autophagic proteolysis, reduces α‐synuclein accumulation, and preserves dopaminergic neuron
Chih Hung Lo, Mengda Ren, Gavin Wen Zhao Loi, Eka Norfaishanty Saipuljumri, Jonathan Indajang, Kah Leong Lim, Jialiu Zeng   +6 more
wiley   +1 more source

An immunoelectron microscopic study of glucocerebrosidase in type 1 Gaucher's disease spleen

, 1988
An immunogold labeling procedure was applied to ultrathin cryosections and used to study the subcellular localization of glucocerebrosidase in lipid-laden "Gaucher cells" in spleen from a patient with type 1 Gaucher's disease.
Goudsmit, R., Willemsen, R., van Dongen, J. M., Aerts, J. M., Tager, J. M., Reuser, A. J., Schram, A. W.   +6 more
core   +1 more source

Novel pathogenic mutations in the glucocerebrosidase locus

Molecular Genetics and Metabolism, 2012
To determine the frequency of mutations responsible for Gaucher's disease, we systematically sequenced the GBA1 gene as part of a molecular characterization of 73 adult patients in the United Kingdom. Five hitherto unknown pathogenic variants were identified, one of which is a splice site change; the others are novel missense mutations. Given that GBA1
Duran, Raquel, McNeill, Alisdair, Mehta, Atul, Hughes, Derralyn, Cox, Timothy, Deegan, Patrick, Schapira, Anthony H.V., Hardy, John   +7 more
openaire   +2 more sources

Ceramides in Parkinson’s Disease: From Recent Evidence to New Hypotheses

Frontiers in Neuroscience, 2019
Ceramides (Cer) constitute a class of lipids present in the cell membranes where they act as structural components, but they can also work as signaling molecules.
Nicoletta Plotegher, Luigi Bubacco, Elisa Greggio, Laura Civiero   +3 more
doaj   +1 more source

Small Extracellular Vesicles from Neural Cells: Physiological and Pathological Roles, and Potential in Neurodegenerative Therapy

Advanced Healthcare Materials, Volume 15, Issue 21, 5 June 2026.
Neural cell–derived small extracellular vesicles (sEVs) are emerging as pivotal mediators in neurodegenerative diseases, exerting both pathogenic and therapeutic functions. This review synthesizes current evidence on how sEVs from distinct neural cell types regulate neurodegeneration, neuroprotection, biomarker discovery, and targeted drug delivery ...
Muhammad Waqas Salim, Wei Zhang, Lyndsey Collins‐Praino, Yuling Wang, Andrew Care   +4 more
wiley   +1 more source

A Human Neural Crest Stem Cell-Derived Dopaminergic Neuronal Model Recapitulates Biochemical Abnormalities in GBA1 Mutation Carriers

Stem Cell Reports, 2017
Numerically the most important risk factor for the development of Parkinson's disease (PD) is the presence of mutations in the glucocerebrosidase GBA1 gene.
Shi-Yu Yang, Michelle Beavan, Kai-Yin Chau, Jan-Willem Taanman, Anthony H.V. Schapira   +4 more
doaj   +1 more source

The Emerging Parkinson's Disease Oxylipin‐Ome

Advanced Science, Volume 13, Issue 33, 15 June 2026.
ABSTRACT Parkinson Disease (PD) is increasingly considered a proteinopathy and lipidopathy. This proteinopathy+lipidopathy paradigm has been further refined to a fatty acid (FA)‐opathy, centering dysregulated FA metabolism as fundamental in PD lipid dysfunction.
Julia C. Kelliher, Saranna Fanning
wiley   +1 more source

Complete screening for glucocerebrosidase mutations in Parkinson disease patients from Portugal [PDF]

, 2008
Mutations in the gene encoding beta-glucocerebrosidase, a lysosomal degrading enzyme, have recently been associated with the development of Parkinson disease.
Morgadinho, A, Januário, C, Sidransky, E, Sidransky, Ellen, Singleton, Andrew, Guerreiro, C, Brás, José, Ribeiro, MH, Ribeiro, Maria Helena, Morgadinho, Ana, Januário, Cristina, Oliveira, CR, Singleton, A, Guerreiro, Rita, Paisan-Ruiz, C, Brás, JM, Paisan-Ruiz, Coro, Oliveira, Catarina   +17 more
core   +1 more source

Genetic Variants and Clinical Characteristics of Young‐Onset Parkinson's Disease in the Hakka Population of Western Fujian

Brain and Behavior, Volume 16, Issue 6, June 2026.
In 33 Hakka young‐onset Parkinson's disease (YOPD) patients from western Fujian, whole exome sequencing (WES) plus spinocerebellar ataxia (SCA) panel testing and multiplex ligation‐dependent probe amplification (MLPA) defined the genetic spectrum. Pathological ATXN2 repeat expansion was detected in two cases.
Li‐Ying Pan, Fang Guo, Chong Zheng, Xiao‐Hong Hu, Yan‐Gui Chen, Rong‐Rong Lin   +5 more
wiley   +1 more source

Progress of Immunotherapies in Parkinson's Disease

CNS Neuroscience &Therapeutics, Volume 32, Issue 6, June 2026.
Parkinson's disease (PD) is caused by an immune disorder triggered by α‐synuclein, leading to a persistent neuroinflammatory cycle that drives the disease from non‐motor symptoms to the motor stage. Second, it presents active and passive immunotherapy strategies targeting α‐synuclein and their potential in slowing down the disease progression.
Yong Peng, Xu‐hui Kang, Shun‐yu Yao, Xiuli Zhang, Sugimoto Kazuo, Jia Liu, Miao‐qiao Du, Lan‐xin Lin, Dai‐yi Jiang, Quan Chen, Hong Jin   +10 more
wiley   +1 more source